MSL
HRTX icon

Mackay Shields LLC’s Heron Therapeutics HRTX Stock Holding History

Mackay Shields LLC’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-74,875
Closed -$1.21M – 984
2021
Q1 		$1.21M Sell
74,875
-44,951
-38% -$801K 0.01% 946
2020
Q4 		$2.54M Sell
119,826
-9,800
-8% -$170K 0.02% 752
2020
Q3 		$1.92M Buy
129,626
+21,200
+20% +$331K 0.01% 808
2020
Q2 		$1.59M Buy
108,426
+35,500
+49% +$583K 0.01% 856
2020
Q1 		$856K Buy
72,926
+10,800
+17% +$203K 0.01% 996
2019
Q4 		$1.46M Sell
62,126
-14,600
-19% -$323K 0.01% 975
2019
Q3 		$1.42M Buy
76,726
+1,800
+2% +$33.1K 0.01% 1030
2019
Q2 		$1.39M Buy
74,926
+50,451
+206% +$1.01M 0.01% 1038
2019
Q1 		$598K Buy
24,475
+500
+2% +$13.1K ﹤0.01% 1144
2018
Q4 		$622K Buy
23,975
+1,575
+7% +$43.3K 0.01% 1086
2018
Q3 		$709K Buy
+22,400
New +$834K 0.01% 945

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Mackay Shields LLC's HRTX Position: Q2 2021 in Review

Mackay Shields LLC sold out of Heron Therapeutics (HRTX) in Q2 2021, closing a stake of 74,875 shares — an estimated $1.21M sold.

Mackay Shields LLC first reported a position in HRTX in Q3 2018 and held it in 11 quarters. The position peaked at $2.54M in Q4 2020. 189 funds tracked by Wall St. Rank hold HRTX as of Q2 2021.

  • Mackay Shields LLC reported no remaining Heron Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 74,875 Heron Therapeutics shares in Q2 2021, an estimated $1.21M.
  • Mackay Shields LLC first reported a position in Heron Therapeutics in Q3 2018 and held it in 11 quarters.
  • Mackay Shields LLC's Heron Therapeutics position peaked at $2.54M in Q4 2020.
  • 189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.